Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5856-5863

  Fetterly, Gerald J ^a,b   Grasela, Thaddeus H ^a   Sherman, Jeffrey W ^c   Dul, Jeanne L ^c   Grahn, Amy ^c   Lecomte, Diane ^c   Fiedler Kelly, Jill ^a   Damjanov, Nevena ^d   Fishman, Mayer ^e   Kane, Michael P ^f   Rubin, Eric H ^f   Tan, Antoinette R ^f  

^a Albany Medical College

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NeoPharm Inc   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DEXAMETHASONE; LIPOSOME; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; AREFLEXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPESTHESIA; HYPOREFLEXIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HUMANS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NEUTROPENIA; PACLITAXEL;

EID: 53249131199     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1046     Document Type: Article

References (26)

1. Jordan MA. Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A1993;90:9552-6.
2. Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61.
3. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8: 1263-8.
4. Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11:8230-4.
5. Sharma A, Mayhew E, Straubinger RM. Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res 1993;53: 5877-81.
6. Sharma A, Straubinger RM, Ojima I, Bernacki RJ. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 1995;84:1400-4.
7. Straubinger RM, Sharma A, Murray M, Mayhew E. Novel Taxol formulations: Taxol-containing liposomes. J Natl Cancer Inst Monogr 1993;15:69-78.
8. Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 2005;59:177-87.
9. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
10. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22:16-23.
11. Fetterly GJ, Tamburlin JM, Straubinger RM. Paclitaxel pharmacodynamics: application of a mechanismbased neutropenia model. Biopharm Drug Dispos 2001;22:251-61.
12. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002;20:4713-21.
13. Friberg LE, Karlsson MO. Mechanistic models for myelosuppression. Invest New Drugs 2003;21:183-94.
14. Joerger M, Huitema AD, Richel DJ, et al. Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: a study by the EORTC-PAMM-NDDG. Br J Clin Pharmacol 2007;63:505.
15. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 2006;12:5481-90.
16. Tan AR, Hanauske AR, Gelderblom H, et al. Results of a clinical pharmacokinetic bioequivalence study of liposomal paclitaxel (LEP-ETU) versus paclitaxel in patients with advanced cancer [abstract 2017]. J Clin Oncol 2006;24:83s.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Vainchtein LD, Thijssen B, Stokvis E, Rosing H, Schellens JH, Beijnen JH. A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. Biomed Chromatogr 2006;20:139-48.
19. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: bestcase performance. J Pharmacokinet Pharmacodyn 2003;30:387-404.
20. Beal SL, Boeckmann AJ, Sheiner LB. NONMEM users guide. Part VI. PREDPP guide; 1992.
21. Holford NHG. The visual predictive check-superiority to standard diagnostic (Rorschach) plots. PAGE 2005;14:738.
22. Fang L, Holford NH, Hinkle G, et al. Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 2007;2: 227-37.
23. Damjanov N, Fishman MN, Steinberg JL, et al. Final results of a phase I study of liposome entrapped paclitaxel (LEP-ETU) in patients with advanced cancer [abstract 2048]. J Clin Oncol 2005;23:147s.
24. Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. Blood 1964; 24:780-803.
25. Winer EP, Berry DA, Woolf S, et al. Failure of higherdose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061-8.
26. Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS Pharm Sci 2003;5:E32.